One of them, Baytree, could even be worth than less than implied six months ago when Alibaba invested in it during pre-IPO funding.
The drug developer will be the second biotech firm to list in Hong Kong without any profits or revenues. It believes that China’s underpenetrated biologics market provides a massive opportunity in the long run.
The regional Chinese lender launches an initial public offering to raise $1.1 billion and looks set to become the third bank classed as a rural financial institution to list in Hong Kong.
Chinese biopharmaceutical firm to list biologics arm in Hong Kong after delisting in New York in 2015. All the signs are it will deliver healthy returns for backers of its privatisation.
Wuxi PharmaTech is looking to relist its biologic arm in Hong Kong after the group was taken private through a management buyout in late 2015.
Chinese private hospital operator launches Asia’s first IPO in the new calendar year.
China Datang Group has launched a second attempt to spin-off its energy conservation business as China tightens emissions standards.
After the successful deal, China Resources Group has now listed six of its subsidiaries in Hong Kong.
China's second-largest drug manufacturer to raise funds for expansion amid industry consolidation.
China's eighth largest brokerage by assets achieves mid-range price in the face of challenging markets for brokerage stocks.
China's eighth largest brokerage by assets also becomes No8 out of the top 10 to attempt a Hong Kong Stock Exchange listing. The IPO is the largest by a brokerage this year.
Similar to other state-owned banks, the post-to-banking lender’s Hong Kong listing is yet another deal dominated by investment from state institutions.
Samsung bought a $450 million stake in Chinese electric car maker BYD last week. Analysts think the move made sense for a company that has had previous China hopes dashed.
Nuclear construction giant CNEC raises $278 million from its long-awaited initial public offering in Shanghai, the second largest A-share flotation so far this year.
Chinese securities firm earnings are under pressure as brokerage fees come off their elevated 2015 levels, making it harder for ECM bankers to bring new offerings to market.
The historically media-shy Chinese logistics giant is looking to fast-track its way onto the market with the help of a Shenzhen-listed rare earth metals firm.
Daniel Ng, who left China Merchants Securities (HK) last October, has returned to Bank of China International to head its investment banking division.
Chinese investment banks and brokerages are hunting for foreign talent amid a surge in outbound M&A opportunities.
Hong Kong-listed construction company breaks drought in equity-linked deals.
The departure of banking industry veteran Daniel Ng comes after more than three years at the Hong Kong brokerage, a unit of state-owned China Merchants Group.